Georgetown research uncovers new mechanism for suppressing HIV

October 03, 2001

(Washington, DC)-- Laboratory studies at Georgetown University Medical Center have shown that Peptide-T -- a synthetic compound of amino acids -- can suppress the human immunodeficiency virus (HIV) by preventing the virus from entering healthy human cells. Whether the same result can be achieved outside the laboratory in human beings will not be known until some time next year, at the conclusion of an ongoing Phase II clinical trial, which is under way at St. Francis Memorial Hospital in San Francisco.

The laboratory research, which was conducted by Michael Ruff, PhD, and Candace Pert, PhD, both research professors in the Department of Physiology and Biophysics at Georgetown University Medical Center, appears in the October issue of the journal Anti-Viral Research.

Peptide-T, which is a member of the newest class of experimental AIDS therapeutics known as "viral entry inhibitors," works by adhering to a certain type of cellular receptor site (known as the chemokine R-5 receptor site), and preventing HIV from entering healthy cells. The compound, in effect, physically "blocks" the HIV and thereby prevents the cells from becoming infected.

This is a different mode of action than that employed by the most commonly used HIV therapy--protease inhibitors, which work by disrupting a key enzyme required for the viral assembly of HIV, so that it can no longer "fit" into cellular receptors.

One likely advantage of Peptide-T over protease inhibitors is that, whereas HIV develops an eventual resistance to the protease inhibitors -- and mutates in such a way that it is eventually able to enter the cells again -- this resistance has not been observed in cells treated with Peptide-T.

"If clinical trials produce the same results as our test tube studies, Peptide-T could one day be a treatment far better than protease inhibitors," Ruff said. "While protease inhibitors have long been a method of treatment for a great many people, there are many drawbacks to this therapy including harmful side effects, great expense, a complicated regimen, and, most importantly, the ability of the virus to mutate and become resistant to the therapy."

Another advantage of Peptide-T over protease inhibitors is that Peptide-T potentially could be given to patients at a much earlier stage than can protease inhibitors, if human trials bear out the laboratory results. Because HIV develops resistance to protease inhibitors over time, they are typically given only after virus levels rise to a certain level (usually 30,000 copies per milliliter of blood) and after the immune system has been significantly damaged.

This means that most patients do not begin HIV therapy until the disease is already fairly advanced, after many cells have been infected with the virus. But because HIV appears not to develop a resistance to Peptide-T-treated cells, it could potentially be given as soon as patients receive a positive diagnosis of HIV infection. And Peptide-T does not appear to cause many of the serious side effects experienced by people being treated with protease inhibitors.

Pert and Ruff's experiments were repeated with similarly decisive results by three independent teams from the National Institutes of Health, the University of Pennsylvania and the University of Puerto Rico.

Their research was funded by Advanced Immunity Inc., a small, privately held New York-based company that licenses the worldwide exclusive rights to Peptide-T. The research was conducted at Georgetown and in the laboratory of Frank Ruscetti, PhD, of the National Cancer Institute, where the HIV strains are housed.

The Phase II clinical trial now under way in San Francisco involves 24 HIV-positive participants who will receive Peptide-T twice a day for six months. To qualify for the trial, patients must have T-cell counts greater than 300 and viral loads (a measurement of the amount of HIV in the blood) of less than 25,000 copies of the virus per milliliter of blood. The trial is currently recruiting participants. Patients who would like to learn more about the clinical trial may call Diane Cenko at 415-353-6215.
To arrange an interview with Pert and Ruff, call Beth Porter at 202-687-4699.

Georgetown University Medical Center includes the nationally ranked School of Medicine, School of Nursing and Health Studies, and a biomedical research enterprise. For more information, please visit

Georgetown University Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to